Publications by authors named "M L Buch"
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.
Objectives: To perform a systematic literature review to inform a Task Force formulating EULAR points to consider on the initiation of targeted therapies in patients with IA and a history of cancer.
Methods: Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian.
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice.
Objectives: To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.
Methods: Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC.
Article Synopsis
- Anti-Ro/SS-A antibodies are common in systemic autoimmune rheumatic diseases (SARDs) and suggest specific patient profiles; this study focused on the connection between protein biomarkers, symptom burden, and health-related quality of life (HR-QoL).
- A pilot study enrolled anti-Ro positive SARD patients over six months, using various scales to measure HR-QoL and symptom burden, while assessing protein levels in the blood through advanced immunoassays.
- Two patient clusters emerged: a 'low expression cluster' with greater symptom severity and poor HR-QoL, and a 'high expression cluster' tied to better physician assessments, highlighting potential protein markers that could lead to new therapeutic strategies for managing these patients.
Background: Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1-preferential inhibitor available in two doses for moderate-to-severe RA. We report the long-term efficacy and safety of filgotinib.
View Article and Find Full Text PDF